NEW YORK, July 22, 2015 /PRNewswire/ -- Seeger Weiss LLP represents hundreds of clients who allege pharmaceutical companies that manufacture testosterone therapy products failed to adequately warn doctors and patients of the cardiovascular risks associated with the drug. A recent study, published this month in the Journal of Clinical Endocrinology & Metabolism, found that men with low testosterone levels due to aging did not experience significant improvement in ejaculatory function after taking testosterone therapy products.
This study showed that in men who exhibited symptoms of low testosterone due to aging—rather than medical conditions—did not experience improved sexual function after using testosterone replacement drugs. The results suggested that doctors who were treating the symptoms of sexual disorders needed to look at causes other than low testosterone to explain ejaculatory dysfunction. Researchers from the study stated that more clinical trials were needed in order to determine treatments for cases of ejaculatory disorders.
The FDA has already cautioned that testosterone products were only recommended for use in men who lack or have low testosterone levels in conjunction with an associated medical condition. In a Safety Announcement dated March 2015, the Agency stated that "the benefit and safety of these medications have not been established for the treatment of low testosterone levels due to aging, even if a man's symptoms seem related to low testosterone."
A September 2014 Advisory Committee to the FDA, concluded that there is a possible increased cardiovascular risk associated with testosterone use and requested that information be added to drug labeling to clarify the approved uses and associated risks of these medications.
Chris Seeger of Seeger Weiss LLP serves as Co-Lead Counsel on behalf of plaintiffs in the multidistrict Testosterone Replacement Therapy Products Liability Litigation, centered in the United States District Court, Northern District of Illinois.
Seeger Weiss LLP is one of the nation's leading trial law firms handling complex individual, mass and class action litigation on behalf of consumers, investors, injured persons and whistleblowers. The firm, with offices in New York, Philadelphia and New Jersey, represents plaintiffs throughout litigation and as trial counsel in a variety of practice areas, including financial, securities and investment fraud, pharmaceutical injury, consumer protection, qui tam (whistleblower cases), environmental and asbestos exposures, personal injury and medical malpractice, product defect, antitrust, and commercial disputes. For more information, go to www.seegerweiss.com.
SOURCE Seeger Weiss LLP